- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Immunosuppressant gets name approval
ISA247, a calcineurin inhibitor currently in phase IIb in North America for the prevention of organ rejection in kidney transplant patients and as a treatment for uveitis, has received approval from the United States Adopted Names Council to call the drug voclosporin.
ISA247, a calcineurin inhibitor currently in phase IIb in North America for the prevention of organ rejection in kidney transplant patients and as a treatment for uveitis, has received approval from the United States Adopted Names Council to call the drug voclosporin. The next step is to request approval for the name by WHO?s International Nonproprietary Names (INN) committee. Once given the nod by INN, the drug will be referred to as voclosporin as its generic name in all future materials. Voclosporin is the lead candidate of Canadian company Isotechnika Inc.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Antiseizure Medications Linked to Serious Potential Reaction, FDA Warns
November 30th 2023Levetiracetam and clobazam can cause Drug Reaction with Eosinophilia and Systemic Symptoms, which can start as a rash but progress quickly, potentially resulting in injury to internal organs, hospitalization, and death.
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
